Targeted Fragments

InFarmatik designes and synthesizes fragment libraries. The libraries have special morphological and biological properties by design. These properties are validated in various ways, including fragment screens. Now the whole consolidated  1700 fragment library is sold as one, compounds and data are available individually.

In3D

concept published FBLD 2010

for download factsheet​ PDF click here

 

GPCR

concept published GCPR 2011 (CHI)

for download factsheet PDF click here

 

Kinase

concept published FBLD 2012

for download factsheet PDF click here

CLASSICAL FRAGMENT PROGRAMS

In3D

In3D concept was validated and accepted by Fragment Community, now "In3D-ness" is a property of value. 

 

GPCR

Tagetex (Hu) developed Ca based cellular assay on CB1 and 5HT6 . Hits reported on a poster FBLD 2014 Basel 

 

OntoChem(D) developed reporter gene assays on D1, H beta2 adrenerg and GPR84. D1 and beta2 hits reported on a poster FBLD 2014 Basel, GPR84 under patent application

 

Kinase

​PIM1 CK2 dual kinase inhibitor project in collaboration with IOTA PHARMACEUTICALS (UK) the dual inhibitors were identified in kianse assays reported on Fragments 2013 Oxford, QSAR UK 2013. The project stopped due to lack of funds, neccesary for X-ray structures and fragment development

  • w-facebook
  • w-blogger

©  Copyright 2022 Business Consulting

This site was designed with the
.com
website builder. Create your website today.
Start Now